Pancreatic enzyme testing reimbursement (lipase/amylase/trypsin/biomarkers)
Defines UnitedHealthcare Medicare Advantage reimbursement rules for serum/urine pancreatic enzyme and related biomarker testing (billed on CMS 1500 or UB04) for evaluation of acute pancreatitis and associated conditions, and who may submit such claims.
Q&A and Definitions sections were updated in the policy version history.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.